乳腺癌：从病理生理学到新的治疗方法 2.0。
Breast Cancer: From Pathophysiology to Novel Therapeutic Approaches 2.0.
机构信息
Institute of Biostructures and Bioimaging, National Research Council (IBB-CNR), 80145 Naples, Italy.
出版信息
Int J Mol Sci. 2023 Jan 29;24(3):2542. doi: 10.3390/ijms24032542.
Abstract
Breast cancer (BC) is the most common malignancy in women worldwide [...].
摘要
乳腺癌（BC）是全世界女性中最常见的恶性肿瘤[...]。
相似文献
1
Breast Cancer: From Pathophysiology to Novel Therapeutic Approaches 2.0.乳腺癌：从病理生理学到新的治疗方法 2.0。
Int J Mol Sci. 2023 Jan 29;24(3):2542. doi: 10.3390/ijms24032542.
2
Advances in systemic therapy for metastatic breast cancer: future perspectives.转移性乳腺癌全身治疗的进展：未来展望。
Med Oncol. 2017 Jul;34(7):119. doi: 10.1007/s12032-017-0975-5. Epub 2017 May 19.
3
Emerging ways to treat breast cancer: will promises be met?新兴的乳腺癌治疗方法：能否兑现承诺？
Cell Oncol (Dordr). 2018 Dec;41(6):605-621. doi: 10.1007/s13402-018-0409-1. Epub 2018 Sep 27.
4
Non-small-cell lung cancer after breast cancer: a population-based study of clinicopathologic characteristics and survival outcomes in 3529 women.乳腺癌后非小细胞肺癌：3529 例女性患者的临床病理特征和生存结局的基于人群研究。
J Thorac Oncol. 2014 Aug;9(8):1081-90. doi: 10.1097/JTO.0000000000000213.
5
Incidence of second primary malignancy after breast cancer and related risk factors-Is breast-conserving surgery safe? A nested case-control study.乳腺癌患者发生第二原发恶性肿瘤的发生率及相关危险因素——保乳手术安全吗？一项巢式病例对照研究。
Int J Cancer. 2020 Jan 15;146(2):352-362. doi: 10.1002/ijc.32259. Epub 2019 Mar 22.
6
Novel role of BRCA1 interacting C-terminal helicase 1 (BRIP1) in breast tumour cell invasion.BRCA1 相互作用的 C 端解旋酶 1（BRIP1）在乳腺癌细胞侵袭中的新作用。
J Cell Mol Med. 2020 Oct;24(19):11477-11488. doi: 10.1111/jcmm.15761. Epub 2020 Sep 5.
7
Breast cancer under age 40: a different approach.40岁以下乳腺癌：一种不同的治疗方法。
Curr Treat Options Oncol. 2015 Apr;16(4):16. doi: 10.1007/s11864-015-0334-8.
8
Survival of Patients with First and Metachronous Second Primary Breast Cancer or Lung Cancer Malignancy: Comparisons Using the SEER Database.基于 SEER 数据库的首发和异时性第二原发性乳腺癌或肺癌患者生存比较。
Adv Ther. 2020 May;37(5):2236-2245. doi: 10.1007/s12325-020-01322-0. Epub 2020 Apr 9.
9
Increased prevalence of primary hyperparathyroidism in treated breast cancer.治疗后乳腺癌患者原发性甲状旁腺功能亢进症患病率增加。
J Endocrinol Invest. 2001 May;24(5):315-20. doi: 10.1007/BF03343867.
10
Lymph node ratio can further stratify prognosis in subpopulations of breast cancer patients with axillary nodal metastases.淋巴结比率可进一步对腋窝淋巴结转移的乳腺癌患者亚群进行预后分层。
Future Oncol. 2013 Oct;9(10):1425-31. doi: 10.2217/fon.13.154.
引用本文的文献
1
Significance of the inflammatory-immune-nutritional (IINS) score on postoperative survival and recurrence in breast cancer patients: a retrospective study.炎症-免疫-营养（IINS）评分对乳腺癌患者术后生存和复发的意义：一项回顾性研究
PeerJ. 2025 Aug 22;13:e19950. doi: 10.7717/peerj.19950. eCollection 2025.
2
Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations.变革乳腺癌治疗：精准医学、纳米技术与药物递送创新的交叉前沿
Curr Treat Options Oncol. 2025 Aug 19. doi: 10.1007/s11864-025-01343-3.
3
Ultrasonic Parameters as Biomarkers for Tumor Staging and Aggressiveness in Breast Cancer: Correlation with GP73 and miR-27a.超声参数作为乳腺癌肿瘤分期和侵袭性的生物标志物：与GP73和miR-27a的相关性
Int J Gen Med. 2025 Jun 21;18:3313-3321. doi: 10.2147/IJGM.S521769. eCollection 2025.
4
The Role of PAX7 in Breast Cancer Prognosis and Its Mechanistic Involvement in the Wnt/β-Catenin Pathway.PAX7在乳腺癌预后中的作用及其在Wnt/β-连环蛋白通路中的机制参与
J Cell Mol Med. 2025 May;29(10):e70602. doi: 10.1111/jcmm.70602.
5
DNMT3A facilitates breast cancer progression via regulating ADAMTS8 mediated EGFR-MEK-ERK activation.DNA甲基转移酶3A通过调控含血小板解聚蛋白基序的金属蛋白酶8介导的表皮生长因子受体-丝裂原活化蛋白激酶激酶-细胞外信号调节激酶激活促进乳腺癌进展。
PLoS One. 2025 May 5;20(5):e0321889. doi: 10.1371/journal.pone.0321889. eCollection 2025.
6
Doublecortin-like kinase 1, regulated by STIP1 homology and U-box containing protein 1 or Sp1 transcription factor, affects the malignant behaviors and drug sensitivity in adriamycin-resistant breast cancer cells.由含STIP1同源性和U盒结构域蛋白1或Sp1转录因子调控的双皮质素样激酶1影响耐阿霉素乳腺癌细胞的恶性行为和药物敏感性。
Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 21. doi: 10.1007/s00210-025-04159-y.
7
Effects of warming needle moxibustion on postoperative rehabilitation, pain degree, immune function, and upper limb lymphedema in patients with breast cancer undergoing radical mastectomy.温针艾灸对乳腺癌根治术患者术后康复、疼痛程度、免疫功能及上肢淋巴水肿的影响。
Am J Cancer Res. 2025 Mar 15;15(3):991-1001. doi: 10.62347/YXHG6188. eCollection 2025.
8
TPD52 as a Therapeutic Target Identified by Machine Learning Shapes the Immune Microenvironment in Breast Cancer.通过机器学习确定的治疗靶点TPD52塑造乳腺癌免疫微环境。
J Cell Mol Med. 2025 Jan;29(1):e70333. doi: 10.1111/jcmm.70333.
9
The emerging role of long non-coding RNA SOX2-OT in cancers and non-malignant diseases.长链非编码RNA SOX2-OT在癌症和非恶性疾病中的新作用。
J Physiol Biochem. 2025 Feb;81(1):57-83. doi: 10.1007/s13105-024-01059-2. Epub 2024 Dec 20.
10
Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation .揭示治疗潜力：KBU2046 通过限制 TGF-β1 激活来阻止三阴性乳腺癌细胞迁移。
Oncol Res. 2024 Oct 16;32(11):1791-1802. doi: 10.32604/or.2024.049348. eCollection 2024.
本文引用的文献
1
Aptamer-Functionalized Nanoparticles Mediate PD-L1 siRNA Delivery for Effective Gene Silencing in Triple-Negative Breast Cancer Cells.适体功能化纳米颗粒介导PD-L1 siRNA递送以实现三阴性乳腺癌细胞中的有效基因沉默
Pharmaceutics. 2022 Oct 18;14(10):2225. doi: 10.3390/pharmaceutics14102225.
2
Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer.CDK9 PROTAC 化合物在 HER2 阳性乳腺癌中的抗肿瘤活性。
Int J Mol Sci. 2022 May 13;23(10):5476. doi: 10.3390/ijms23105476.
3
Optimization of Short RNA Aptamers for TNBC Cell Targeting.优化用于三阴性乳腺癌细胞靶向的短 RNA 适体。
Int J Mol Sci. 2022 Mar 23;23(7):3511. doi: 10.3390/ijms23073511.
4
Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular Subtypes of Breast Cancer.芦可替尼和骨化三醇联合治疗对乳腺癌不同分子亚型的影响。
Int J Mol Sci. 2022 Feb 25;23(5):2535. doi: 10.3390/ijms23052535.
5
Involvement of Mitochondrial Mechanisms and Cyclooxygenase-2 Activation in the Effect of Desethylamiodarone on 4T1 Triple-Negative Breast Cancer Line.线粒体机制和环氧化酶-2 激活参与了去乙基胺碘酮对 4T1 三阴性乳腺癌细胞系的作用。
Int J Mol Sci. 2022 Jan 28;23(3):1544. doi: 10.3390/ijms23031544.
6
The Other Side of the Coin: May Androgens Have a Role in Breast Cancer Risk?硬币的另一面：雄激素在乳腺癌风险中可能发挥作用？
Int J Mol Sci. 2021 Dec 31;23(1):424. doi: 10.3390/ijms23010424.
7
Transcriptome Profile Analysis of Triple-Negative Breast Cancer Cells in Response to a Novel Cytostatic Tetrahydroisoquinoline Compared to Paclitaxel.三重阴性乳腺癌细胞对新型细胞抑制剂四氢异喹啉与紫杉醇反应的转录组谱分析。
Int J Mol Sci. 2021 Jul 19;22(14):7694. doi: 10.3390/ijms22147694.
8
Optimizing cisplatin delivery to triple-negative breast cancer through novel EGFR aptamer-conjugated polymeric nanovectors.通过新型表皮生长因子受体适配体缀合的聚合物纳米载体优化顺铂对三阴性乳腺癌的递送。
J Exp Clin Cancer Res. 2021 Jul 22;40(1):239. doi: 10.1186/s13046-021-02039-w.
9
Mechanism of Anticancer Action of Novel Imidazole Platinum(II) Complex Conjugated with G2 PAMAM-OH Dendrimer in Breast Cancer Cells.新型咪唑铂（II）配合物与 G2 PAMAM-OH 树枝状聚合物偶联物在乳腺癌细胞中的抗癌作用机制。
Int J Mol Sci. 2021 May 25;22(11):5581. doi: 10.3390/ijms22115581.
10
MAT2A Localization and Its Independently Prognostic Relevance in Breast Cancer Patients.MAT2A 在乳腺癌患者中的定位及其独立预后相关性。
Int J Mol Sci. 2021 May 20;22(10):5382. doi: 10.3390/ijms22105382.
Zotero 插件